ES2939760T3 - Tratamiento de cáncer utilizando un receptor quimérico para antígenos - Google Patents

Tratamiento de cáncer utilizando un receptor quimérico para antígenos Download PDF

Info

Publication number
ES2939760T3
ES2939760T3 ES15712503T ES15712503T ES2939760T3 ES 2939760 T3 ES2939760 T3 ES 2939760T3 ES 15712503 T ES15712503 T ES 15712503T ES 15712503 T ES15712503 T ES 15712503T ES 2939760 T3 ES2939760 T3 ES 2939760T3
Authority
ES
Spain
Prior art keywords
antigen
cell
car
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15712503T
Other languages
English (en)
Spanish (es)
Inventor
Andreas Loew
Michael C Milone
Daniel J Powell
Yangbing Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
University of Pennsylvania Penn
Original Assignee
Novartis AG
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52780057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2939760(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, University of Pennsylvania Penn filed Critical Novartis AG
Application granted granted Critical
Publication of ES2939760T3 publication Critical patent/ES2939760T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
ES15712503T 2014-03-15 2015-03-13 Tratamiento de cáncer utilizando un receptor quimérico para antígenos Active ES2939760T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461953783P 2014-03-15 2014-03-15
US201461976375P 2014-04-07 2014-04-07
US201462027154P 2014-07-21 2014-07-21
US201462076146P 2014-11-06 2014-11-06
US201462097286P 2014-12-29 2014-12-29
PCT/US2015/020606 WO2015142675A2 (en) 2014-03-15 2015-03-13 Treatment of cancer using chimeric antigen receptor

Publications (1)

Publication Number Publication Date
ES2939760T3 true ES2939760T3 (es) 2023-04-26

Family

ID=52780057

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15712503T Active ES2939760T3 (es) 2014-03-15 2015-03-13 Tratamiento de cáncer utilizando un receptor quimérico para antígenos

Country Status (6)

Country Link
US (2) US20170335281A1 (enrdf_load_stackoverflow)
EP (2) EP3119423B1 (enrdf_load_stackoverflow)
JP (4) JP2017513818A (enrdf_load_stackoverflow)
CN (1) CN106163547A (enrdf_load_stackoverflow)
ES (1) ES2939760T3 (enrdf_load_stackoverflow)
WO (1) WO2015142675A2 (enrdf_load_stackoverflow)

Families Citing this family (487)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
UY35340A (es) 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
EP3626741A1 (en) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EP3623380A1 (en) 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
KR102095700B1 (ko) 2013-05-14 2020-04-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
CN105979967A (zh) 2013-09-18 2016-09-28 奥拉生物科学公司 用于诊断和治疗肿瘤的病毒样颗粒缀合物
MX2016008076A (es) 2013-12-19 2016-08-12 Novartis Ag Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10125193B2 (en) 2014-02-14 2018-11-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
EP3119423B1 (en) 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
SG11201608395PA (en) 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Defined composition gene modified t-cell products
WO2015179801A1 (en) 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
EP3172234B1 (en) 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
JP2017528433A (ja) * 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
RU2741120C2 (ru) * 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
US10273295B2 (en) * 2014-08-19 2019-04-30 Miltenyi Biotec Gmbh Chimeric antigen receptor specific for SSEA4 antigen
EP3183268B1 (en) 2014-08-19 2020-02-12 Novartis AG Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL279420B2 (en) 2014-10-08 2024-09-01 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
AU2015358400B2 (en) 2014-12-03 2020-09-10 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
MX385156B (es) 2014-12-05 2025-03-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico que se dirigen al receptor acoplado a la proteína g y sus usos.
RU2766094C2 (ru) 2014-12-05 2022-02-07 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
MX395028B (es) * 2014-12-05 2025-03-24 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos.
EP4310097A3 (en) 2014-12-05 2024-04-03 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CA2969886A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
CN107567461A (zh) 2014-12-29 2018-01-09 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
CN107438618A (zh) 2015-01-26 2017-12-05 塞勒克提斯公司 赋予结合至cd123的嵌合抗原受体用于治疗复发性/难治性急性骨髓性淋巴瘤或母细胞性浆细胞样树突状细胞肿瘤的t细胞受体敲除的工程化免疫细胞
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016130598A1 (en) 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
WO2016134284A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
KR102606190B1 (ko) 2015-02-20 2023-11-23 오하이오 스테이트 이노베이션 파운데이션 Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
WO2016138846A1 (en) 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
US9777064B2 (en) 2015-03-17 2017-10-03 Chimera Bioengineering, Inc. Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
AU2016246457B2 (en) 2015-04-06 2020-10-15 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
ES2701338T3 (es) * 2015-07-29 2019-02-21 Onkimmune Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen mayor citotoxicidad
JP7409773B2 (ja) 2015-07-31 2024-01-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 改変された細胞および治療の方法
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US11890301B2 (en) * 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
CN108350605A (zh) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
WO2017053889A2 (en) * 2015-09-23 2017-03-30 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
CN105567649A (zh) * 2015-10-26 2016-05-11 哈尔滨新联合生物科技有限公司 一种修饰的增强型dc-cik靶向免疫细胞群的制备方法和用途
WO2017075147A1 (en) * 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
CA3002674A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
MX2018005468A (es) * 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Terapia dirigida contra el cáncer.
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
UA121914C2 (uk) * 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
JP2019500028A (ja) 2015-11-19 2019-01-10 ブラッドセンター リサーチ ファウンデーション 癌免疫療法で使用するための二重特異性ｔ細胞を製造する方法
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
SG11201804656PA (en) 2015-12-04 2018-06-28 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
US11052111B2 (en) * 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
JP2019500874A (ja) 2015-12-28 2019-01-17 ノバルティス アーゲー キメラ抗原受容体発現細胞の作製方法
SG11201805451TA (en) 2015-12-30 2018-07-30 Novartis Ag Immune effector cell therapies with enhanced efficacy
WO2017122019A1 (en) 2016-01-12 2017-07-20 Crescendo Biologics Limited Immunoconjugates that bind prostate specific membrane antigen (psma)
EP3405496B1 (en) 2016-01-20 2023-10-25 University of Florida Research Foundation, Incorporated Ror1 antibody compositions and related methods
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
WO2017144681A1 (en) * 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
US20200281973A1 (en) 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
AU2017235097B2 (en) * 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR102584300B1 (ko) 2016-03-29 2023-10-05 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
SG11201808411RA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
CN109641956A (zh) * 2016-04-01 2019-04-16 美国安进公司 Flt3的嵌合受体及其使用方法
PE20190120A1 (es) 2016-04-01 2019-01-17 Kite Pharma Inc Moleculas de union a bcma y metodos de uso de las mismas
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
EA201891992A1 (ru) 2016-04-01 2019-08-30 Кайт Фарма, Инк. Химерные рецепторы и способы их применения
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
EP3440191A4 (en) * 2016-04-07 2019-12-11 Bluebird Bio, Inc. CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US11859208B2 (en) * 2016-04-08 2024-01-02 Emory University Methods of treating cancer using cell based therapies
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
ES2764805T3 (es) * 2016-04-12 2020-06-04 Philogen Spa Terapia de combinación que comprende una inmunocitocina inflamatoria y una célula T con receptor de antígeno quimérico (CAR)
CN106399255B (zh) * 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
IL312206A (en) 2016-04-15 2024-06-01 Novartis Ag Compositions and methods for selective protein expression
CN105907719B (zh) * 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
WO2017190096A1 (en) * 2016-04-29 2017-11-02 University Of Florida Research Foundation Incorporated Chimeric antigen receptors and uses thereof
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
WO2017201019A1 (en) 2016-05-17 2017-11-23 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
EP3464366A1 (en) * 2016-05-27 2019-04-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3484477B1 (en) 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer
WO2018012895A1 (ko) * 2016-07-14 2018-01-18 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN106220736B (zh) * 2016-07-20 2020-01-10 深圳市体内生物医药科技有限公司 一种嵌合抗原受体、表达其的细胞及其制备方法和用途
JP2019530431A (ja) * 2016-07-26 2019-10-24 テッサ・セラピューティクス・プライベート・リミテッド キメラ抗原受容体
CA3032049C (en) 2016-07-27 2023-11-07 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
TW202508628A (zh) 2016-07-28 2025-03-01 瑞士商諾華公司 嵌合抗原受體及pd-1抑制劑之組合療法
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
WO2018026819A2 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3000514A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
CA3032838A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
RU2767206C2 (ru) * 2016-08-12 2022-03-16 Тулджен Инкорпорейтед Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента
KR102659468B1 (ko) * 2016-08-18 2024-04-22 더 유에이비 리서치 파운데이션 암 면역요법을 위한 조성물 및 방법
WO2018045034A1 (en) * 2016-08-30 2018-03-08 Promab Biotechnologies, Inc. Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
WO2018045177A1 (en) 2016-09-01 2018-03-08 Chimera Bioengineering, Inc. Gold optimized car t-cells
CN107793482A (zh) * 2016-09-06 2018-03-13 广州百尼夫生物科技有限公司 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
AU2017322414A1 (en) * 2016-09-08 2019-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
CN106434563B (zh) * 2016-09-14 2017-09-22 深圳市默赛尔生物医学科技发展有限公司 转基因自然杀伤细胞及其制备方法和应用
EP4596707A2 (en) 2016-09-19 2025-08-06 University of Southern California Non-radioactive cytotoxicity assays
WO2018057915A1 (en) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Engineered lymphocytes
CN107868791B (zh) * 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
CN106317228A (zh) * 2016-09-28 2017-01-11 李华顺 一种嵌合抗原受体分子及其应用
WO2018064387A1 (en) 2016-09-28 2018-04-05 Novartis Ag Porous membrane-based macromolecule delivery system
EP3519562A4 (en) * 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3036926C (en) * 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
KR102717188B1 (ko) 2016-10-07 2024-10-16 노파르티스 아게 암의 치료를 위한 키메라 항원 수용체
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
JP7213799B2 (ja) * 2016-10-10 2023-01-27 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 非細胞傷害性改変細胞およびその使用
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
BR112019006652A2 (pt) 2016-10-13 2019-07-02 Juno Therapeutics Inc métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
AU2017346885B2 (en) 2016-10-18 2021-10-21 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
EP3529353A4 (en) * 2016-10-19 2020-05-13 City of Hope USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY
CN107988164B (zh) 2016-10-26 2020-07-07 阿思科力(苏州)生物科技有限公司 一种pd-1 car nk-92细胞及其制备方法与应用
CN106591363A (zh) * 2016-11-11 2017-04-26 广东万海细胞生物科技有限公司 一种通用型异体car‑t细胞制备方法及应用
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CA3044682A1 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
CA3045508A1 (en) * 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for modulation of car-t cells
AU2017368331A1 (en) * 2016-12-03 2019-06-13 Acerta Pharma B.V. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
ES2926397T3 (es) 2016-12-09 2022-10-26 Onk Therapeutics Ltd Células asesinas naturales manipuladas y usos de las mismas
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CA3047999A1 (en) * 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018115458A1 (en) * 2016-12-23 2018-06-28 Virttu Biologics Limited Treatment of cancer
CN107286246B (zh) * 2016-12-28 2019-12-17 时力生物科技（北京）有限公司 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
KR20240128814A (ko) 2017-01-10 2024-08-27 프레시전 인코포레이티드 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
US11541076B2 (en) * 2017-01-13 2023-01-03 Celdara Medical, Llc Chimeric antigen receptors targeting TIM-1
CN110382535A (zh) 2017-01-17 2019-10-25 第一三共株式会社 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
WO2018136606A1 (en) * 2017-01-18 2018-07-26 Thalia Papayannopoulou Compositions and methods for transplant recipient conditioning
CN108330133B (zh) * 2017-01-20 2020-06-30 上海恒润达生生物科技有限公司 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
KR20190133160A (ko) * 2017-02-07 2019-12-02 다이이찌 산쿄 가부시키가이샤 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
JP2020508080A (ja) * 2017-02-21 2020-03-19 ユーティレックス カンパニー リミテッド Ｈｌａ−ｄｒ ｃａｒ−ｔ組成物ならびにその作製方法および使用方法
WO2018169948A1 (en) * 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
US20190358343A1 (en) * 2017-03-20 2019-11-28 University Of Southern California Adoptive transfer of car t cells with surface-conjugated drug-loaded nanoparticles and uses thereof
EA201992232A1 (ru) 2017-03-22 2020-05-14 Новартис Аг Композиции и способы для иммуноонкологии
CN107271675B (zh) * 2017-03-24 2020-06-02 郑猛 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用
SG11201908796XA (en) * 2017-03-27 2019-10-30 Hoffmann La Roche Improved antigen binding receptors
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
KR20240059648A (ko) 2017-04-19 2024-05-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CN109790518A (zh) * 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CN118389602A (zh) 2017-05-08 2024-07-26 株式会社图尔金 经人工操纵的免疫细胞
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CA3062506A1 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018210279A1 (zh) * 2017-05-16 2018-11-22 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
CN110709424B (zh) * 2017-05-31 2024-01-05 科济生物医药（上海）有限公司 细胞免疫治疗的组合物和方法
CA3065126A1 (en) * 2017-06-01 2018-12-06 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cell preparation and uses thereof
CN108977453A (zh) * 2017-06-02 2018-12-11 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用
CN110831970B (zh) 2017-06-02 2024-12-17 辉瑞公司 靶向flt3的嵌合抗原受体
CA3063169A1 (en) * 2017-06-07 2018-12-13 The General Hospital Corporation T cells expressing a chimeric antigen receptor
CA3067244A1 (en) * 2017-06-12 2018-12-20 Emory University T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
CN109134660B (zh) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
JP2020525010A (ja) * 2017-06-22 2020-08-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 制御性免疫細胞を産生するための方法及びその使用
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CN107164412B (zh) * 2017-06-30 2020-10-23 山东兴瑞生物科技有限公司 一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN109232742B (zh) * 2017-07-11 2021-10-22 深圳市第二人民医院 一种嵌合抗原受体及其应用
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
CN107353325B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽1及其应用
CN107326014B (zh) * 2017-07-31 2019-09-24 时力生物科技（北京）有限公司 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
RU2764031C2 (ru) 2017-08-07 2022-01-12 ЭнБиИ - ТЕРАПЬЮТИКС АГ Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
WO2019036855A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
BR112020003646A2 (pt) 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
KR20250047840A (ko) 2017-08-31 2025-04-04 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
CN111065410A (zh) * 2017-09-06 2020-04-24 弗雷德哈钦森癌症研究中心 用于改善过继细胞疗法的方法
JP2020537635A (ja) * 2017-09-15 2020-12-24 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 継続管理及び継続識別による生体サンプル追跡を用いた患者固有の免疫療法手順を実施する方法及びシステム
WO2019067677A1 (en) 2017-09-29 2019-04-04 Cell Design Labs, Inc. METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
CN107557341B (zh) * 2017-09-30 2020-06-30 山东兴瑞生物科技有限公司 一种抗wt1增强型嵌合抗原受体修饰的免疫细胞及其应用
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019070704A1 (en) * 2017-10-02 2019-04-11 Georgia Tech Research Corporation METHODS AND COMPOSITIONS FOR ENGINEERING SYNTHESIS BIOLOGICAL SWITCHES FOR REMOTE CONTROL OF BIOLOGICAL ACTIVITY
CA3078472A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
JP7227630B2 (ja) * 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018351050A1 (en) 2017-10-18 2020-05-07 Novartis Ag Compositions and methods for selective protein degradation
JP2021502330A (ja) * 2017-10-20 2021-01-28 フレッド ハッチンソン キャンサー リサーチ センター Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
CA3080395A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
SG11202003978UA (en) 2017-11-13 2020-05-28 Crescendo Biologics Ltd Molecules that bind to cd137 and psma
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
CA3082328A1 (en) 2017-11-14 2019-05-23 Green Cross Lab Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN107916269B (zh) * 2017-11-17 2020-12-11 山东兴瑞生物科技有限公司 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
AU2018370853A1 (en) * 2017-11-21 2020-05-21 Novartis Ag Trispecific binding molecules against tumor-associated antigens and uses thereof
WO2019111250A1 (en) * 2017-12-05 2019-06-13 The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center T-cells comprising two different chimeric antigen receptors and uses thereof
PL3720883T3 (pl) 2017-12-05 2023-09-11 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Komórki t zawierające chimeryczne receptory antygenowe anty-cd38 i anty-cd138 oraz ich zastosowania
MA51158A (fr) * 2017-12-14 2020-10-21 Bluebird Bio Inc Récepteurs daric nkg2d
KR102752985B1 (ko) * 2017-12-20 2025-01-10 포세이다 테라퓨틱스, 인크. Vcar 조성물 및 사용 방법
IL275177B2 (en) 2017-12-22 2024-05-01 Fate Therapeutics Inc Enhanced effector training cells and their use
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
CN109971722B (zh) * 2017-12-28 2023-09-01 上海细胞治疗研究院 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN111655271A (zh) * 2017-12-28 2020-09-11 科迪亚克生物科学公司 用于免疫肿瘤学和抗炎疗法的外来体
WO2019133760A1 (en) * 2017-12-28 2019-07-04 NEUGATE PHARMA, LLC aka NEUGATE THERANOSTICS Compositions and formulations for treatment of malignancies
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
CN108103105A (zh) * 2017-12-29 2018-06-01 深圳市茵冠生物科技有限公司 一种car-t细胞的制备方法、制得的car-t细胞及其应用
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
WO2019136432A1 (en) * 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3737400A4 (en) 2018-01-09 2021-10-27 H. Lee Moffitt Cancer Center & Research Institute, Inc. COMPOSITIONS AND METHODS FOR TARGETING CLEC12A-EXPRESSING CANCERS
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
ES2990966T3 (es) 2018-01-12 2024-12-02 Curocell Inc Células inmunes mejoradas utilizando ARNsh doble y composición que las incluye
WO2019143818A1 (en) * 2018-01-17 2019-07-25 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
ES2960686T3 (es) * 2018-01-19 2024-03-06 Miltenyi Biotec Bv & Co Kg Células T reguladoras que expresan un receptor de antígeno quimérico
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN110093351B (zh) * 2018-01-29 2023-06-23 华南生物医药研究院 可分离的核酸、多肽、重组载体、重组细胞及应用
US20210038659A1 (en) * 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3806870A4 (en) 2018-02-13 2021-12-22 Chimera Bioengineering, Inc. COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
EP3752599A1 (en) 2018-02-16 2020-12-23 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
EP3762410A4 (en) 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania CHEMICAL PROSTATE MEMBRANE SPECIFIC ANTIGEN SPECIFIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
WO2019170147A1 (zh) * 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
WO2019183389A1 (en) 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US10688182B2 (en) * 2018-03-29 2020-06-23 Cho Pharma Usa, Inc. Monoclonal antibodies that bind to SSEA4 and uses thereof
WO2019192972A1 (en) * 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
US20190328781A1 (en) * 2018-04-06 2019-10-31 Mustang Bio, Inc. Manufacturing methods for cell-based therapeutic compositions
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN112752767A (zh) * 2018-04-27 2021-05-04 克里斯珀医疗股份公司 细胞毒性t细胞耗竭的方法和组合物
US20210094994A1 (en) * 2018-04-27 2021-04-01 Baylor College Of Medicine Car t cells with one or more interleukins
US12201659B2 (en) 2018-04-27 2025-01-21 Mayo Foundation For Medical Education And Research Foamy viruses and methods of use
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN110438082B (zh) * 2018-05-04 2024-03-08 恺兴生命科技(上海)有限公司 表达il-21r结合蛋白的免疫效应细胞
AU2019266398A1 (en) 2018-05-11 2020-11-19 Crispr Therapeutics Ag Methods and compositions for treating cancer
CA3099831A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
BR112020023187A2 (pt) 2018-05-16 2021-04-20 Janssen Biotech, Inc. métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
CN108623683B (zh) * 2018-05-30 2021-06-04 福州迈新生物技术开发有限公司 抗Pax-5蛋白的单克隆抗体及其细胞株、制备方法和应用
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
AU2019276647A1 (en) * 2018-06-01 2020-12-24 Obi Pharma, Inc. Combination therapy by using anti-Globo H or anti-SSEA-4 antibody with anti-negative immune check points antibody
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
CN110577604A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
AU2019288733C1 (en) 2018-06-22 2023-08-03 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
JP7611705B2 (ja) * 2018-06-22 2025-01-10 ザ ジェネラル ホスピタル コーポレイション Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体
CN110623980A (zh) * 2018-06-25 2019-12-31 深圳宾德生物技术有限公司 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用
CN108866004A (zh) * 2018-06-26 2018-11-23 奥妙生物技术（广州）有限公司 Shp-1敲除的t细胞及其构建方法
CN108913709A (zh) * 2018-06-26 2018-11-30 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
WO2020000465A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种制备lightr基因敲除小鼠的方法
US11001635B2 (en) * 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3108460A1 (en) * 2018-07-04 2020-01-09 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
CA3105415A1 (en) * 2018-07-09 2020-01-23 Multitude Inc. Antibodies specific to folate receptor alpha
EP3820571A1 (en) * 2018-07-10 2021-05-19 University of Connecticut Reagents and methods for treating cancer and autoimmune disease
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
KR20210038625A (ko) 2018-07-31 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
SG11202100616VA (en) * 2018-08-07 2021-03-30 Purdue Research Foundation Rejuvenation of car t cell
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
BR112021002579A2 (pt) * 2018-08-10 2021-05-11 Sangamo Therapeutics France novas construções de car compreendendo os domínios de tnfr2
WO2020046766A1 (en) * 2018-08-26 2020-03-05 Oaiscell Biotechnologies Method for treating glioblastoma
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20200080056A1 (en) * 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN109265561B (zh) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用
IL297931B2 (en) 2018-09-25 2025-03-01 Harpoon Therapeutics Inc DLL3 binding proteins and methods of use
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
MX2021004058A (es) * 2018-10-10 2021-06-04 Zymeworks Inc Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment
KR20210081346A (ko) * 2018-10-19 2021-07-01 리전츠 오브 더 유니버시티 오브 미네소타 Nk 관여 분자 및 이의 사용 방법
WO2020081988A1 (en) * 2018-10-19 2020-04-23 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptor targeting sialyl lewis a and uses thereof
US20210379149A1 (en) * 2018-10-25 2021-12-09 Innovative Cellular Therapeutics Holdings, Ltd. Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
WO2020097530A2 (en) * 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunotherapy targeting mesothelin
CN113330034A (zh) 2018-11-16 2021-08-31 阿尔伯特爱因斯坦医学院 针对B7-H3的IgV结构域的单克隆抗体及其用途
CN113286813A (zh) * 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
US10918667B2 (en) * 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020113098A1 (en) 2018-11-29 2020-06-04 Vineti Inc. Centralized and decentralized individualized medicine platform
WO2020123691A2 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc Chimeric antigen and t cell receptors and methods of use
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US20220016171A1 (en) * 2018-12-18 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
EA202191939A1 (ru) * 2019-01-18 2021-10-12 Янссен Байотек, Инк. Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
EP4538380A3 (en) 2019-02-22 2025-07-02 Garvan Institute of Medical Research Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN113874490A (zh) * 2019-04-17 2021-12-31 车比奥泰有限公司 一种抗癌活性增加的自然杀伤细胞以及其免疫治疗用途
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3959236A4 (en) * 2019-04-26 2023-01-25 The University of North Carolina at Chapel Hill CONSTRUCTIONS OF CHEMERA ANTIGEN RECEPTORS AND THEIR USE IN CAR-T CELLS
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
KR20220016083A (ko) 2019-04-30 2022-02-08 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
AU2020266841A1 (en) * 2019-04-30 2021-11-25 Memorial Sloan-Kettering Cancer Center Combination therapies
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
KR20220016475A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
SG11202111281TA (en) 2019-05-21 2021-12-30 Novartis Ag Cd19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
BR112021025735A2 (pt) 2019-06-21 2022-03-08 Kite Pharma Inc Receptores de tgf-ss e métodos de uso
US20220348928A1 (en) * 2019-07-17 2022-11-03 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
CN114728020A (zh) * 2019-07-24 2022-07-08 优瑞科生物技术公司 表达嵌合抗原受体和嵌合刺激受体的细胞及其用途
EP4003418A4 (en) * 2019-07-30 2023-08-16 DendroCyte BioTech Pty Ltd IMMUNE CONJUGATES
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
EP4013431A4 (en) 2019-08-18 2024-05-01 Chimera Bioengineering, Inc. Combination therapy with gold controlled transgenes
CN110627909B (zh) * 2019-08-28 2021-03-30 中国人民解放军第二军医大学 一种特异性活化nk细胞的嵌合抗原受体及其应用
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP7682859B2 (ja) * 2019-09-11 2025-05-26 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 前立腺幹細胞抗原（ｐｓｃａ）キメラ抗原受容体（ｃａｒ）を含む組成物および方法
EP4032972A4 (en) * 2019-09-18 2024-07-24 Slbigen Inc. GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NEW CHIMERIC ANTIGEN RECEPTOR AND ITS USE
WO2021057906A1 (zh) * 2019-09-25 2021-04-01 科济生物医药（上海）有限公司 表达il-15的免疫效应细胞
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
JP7690468B2 (ja) * 2019-10-22 2025-06-10 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ
AU2020370292A1 (en) * 2019-10-23 2022-03-03 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof
CN114423497A (zh) * 2019-10-23 2022-04-29 库尔生物制药有限公司 修饰的细胞毒性t细胞及其使用方法
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
CN110627903B (zh) * 2019-10-29 2021-09-21 河南大学 抗cd97单克隆抗体、其可变区与恒定区序列及应用
WO2021092007A1 (en) * 2019-11-04 2021-05-14 Verastem, Inc. Methods of making cellular therapies
PH12022551290A1 (en) 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
JP7578869B2 (ja) * 2019-11-28 2024-11-07 セントリックスバイオ インコーポレイテッド Ｃｄ３００ｃ抗原またはその受容体に特異的に結合するキメラ抗原受容体
US20210188990A1 (en) * 2019-12-11 2021-06-24 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2021127428A1 (en) * 2019-12-18 2021-06-24 Albert Einstein College Of Medicine Chimeric antigen receptors targeting b7-h3 (cd276) and associated methods
IL293834A (en) 2019-12-20 2022-08-01 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
MX2022008415A (es) * 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
JP2023510353A (ja) * 2020-01-10 2023-03-13 ティーシーアール２ セラピューティクス インク． 自己免疫制御のための組成物及び方法
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2021173985A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3181566A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
BR112022022353A2 (pt) * 2020-05-05 2023-03-14 Tcr2 Therapeutics Inc Composições e métodos para reprogramação de tcr usando proteínas de fusão específicas de cd70
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
KR20220166837A (ko) * 2020-06-11 2022-12-19 난징 바이오흐엥 바이오테크 씨오., 엘티디 Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도
US20230416359A1 (en) * 2020-06-17 2023-12-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer
JPWO2021256522A1 (enrdf_load_stackoverflow) * 2020-06-17 2021-12-23
US20230235074A1 (en) * 2020-06-19 2023-07-27 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform
CN116813777A (zh) 2020-06-22 2023-09-29 恩格姆生物制药公司 Lair-1结合剂及其使用方法
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
EP4182337A1 (en) 2020-07-17 2023-05-24 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US12077594B2 (en) * 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine, Inc. Compositions and methods related to il27 receptor binding
MX2023001491A (es) * 2020-08-05 2023-03-08 Synthekine Inc Moleculas de union a gp130 y metodos de uso.
EP4192852A4 (en) 2020-08-05 2025-07-23 Synthekine Inc IL10RA-BINDING MOLECULES AND METHODS OF USE
US12157773B2 (en) 2020-08-05 2024-12-03 Synthekine, Inc. IL27RAlpha binding molecules and methods of use
EP4192880A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. IL10 receptor-binding molecules and methods of use
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
JP2023545681A (ja) * 2020-09-30 2023-10-31 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ Ｅｇｆｒを標的とするキメラ抗原受容体
CN114369168B (zh) * 2020-10-19 2024-08-30 南京卡提医学科技有限公司 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
JP7688434B2 (ja) * 2020-11-20 2025-06-04 ブリス バイオファーマシューティカル（ハンゾウ）カンパニー，リミテッド 親和性が低下した改変ｅｇｆｒ抗体、薬物複合体及びその使用
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
CN113896795B (zh) 2020-12-11 2022-07-15 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
WO2022147075A1 (en) * 2020-12-30 2022-07-07 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
JP2024504728A (ja) 2021-01-26 2024-02-01 サイトケアズ （シャンハイ） インコーポレイテッド キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞
CN116761889A (zh) * 2021-01-29 2023-09-15 明慧医药（杭州）有限公司 抗原结合蛋白及其用途
JP2024505955A (ja) * 2021-02-03 2024-02-08 バイオヘン セラピューティクス リミテッド 新型キメラ抗原受容体及びその使用
CN112851826B (zh) * 2021-02-10 2023-08-11 上海煦顼技术有限公司 Upk2嵌合抗原受体及其尿道癌的治疗
KR102671410B1 (ko) * 2021-03-03 2024-06-04 진화섭 RANK 리간드(RANK ligand)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
JP7690597B2 (ja) 2021-03-11 2025-06-10 カイト ファーマ インコーポレイテッド 免疫細胞機能の改善
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022247756A1 (zh) * 2021-05-23 2022-12-01 上海邦耀生物科技有限公司 靶向gprc5d的嵌合抗原受体及其用途
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
CN119120424A (zh) 2021-11-02 2024-12-13 辉大(上海)生物科技有限公司 一种CRISPR-Cas12i系统
EP4493581A1 (en) * 2022-03-18 2025-01-22 University of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
CN114805584B (zh) * 2022-06-30 2022-09-09 上海优替济生生物医药有限公司 抗原结合蛋白及其用途
WO2024014470A1 (ja) * 2022-07-13 2024-01-18 国立大学法人大阪大学 腫瘍の予防および／または治療剤
EP4577234A1 (en) 2022-08-26 2025-07-02 Kite Pharma, Inc. Improving immune cell function
CN119907680A (zh) 2022-09-15 2025-04-29 诺华股份有限公司 使用嵌合抗原受体疗法的自身免疫性障碍的治疗
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
US12257304B2 (en) 2023-03-03 2025-03-25 Arsenal Biosciences, Inc. Systems targeting PSMA and CA9
WO2024215987A1 (en) * 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) * 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2025007073A2 (en) 2023-06-29 2025-01-02 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025038646A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US504048A (en) 1893-08-29 Sulky
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
CA2135408A1 (en) 1992-05-08 1993-11-25 Peter C. Keck Chimeric multivalent protein analogues and methods of use thereof
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5843674A (en) 1993-11-16 1998-12-01 Pola Chemical Industries Inc. Anti-human tyrosinase monoclonal antibody
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
ATE191218T1 (de) 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0756604A1 (en) 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
ATE186745T1 (de) 1995-01-18 1999-12-15 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO1996037621A2 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
ES2225961T3 (es) 1996-04-04 2005-03-16 Unilever N.V. Proteina de union a antigeno multivalente y multiespecifica.
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2270154A1 (en) 1996-10-25 1998-04-30 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
CA2304254C (en) 1997-06-11 2012-05-22 Hans Christian Thogersen Trimerising module
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
ATE283364T1 (de) 1998-01-23 2004-12-15 Vlaams Interuniv Inst Biotech Mehrzweck-antikörperderivate
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
EP1073465B1 (en) 1998-04-15 2005-06-22 The Brigham And Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6803448B1 (en) 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
WO2000006605A2 (en) 1998-07-28 2000-02-10 Micromet Ag Heterominibodies
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
HU227008B1 (en) 1999-08-17 2010-04-28 Apotech R & D Sa Use of baff receptor (bcma) as an immunoregulatory agent
DE60010098T2 (de) 1999-08-24 2005-03-31 Ariad Gene Therapeutics, Inc., Cambridge 28-epirapaloge
US7253263B1 (en) 1999-09-30 2007-08-07 Kyowa Hakko Kogyo Co., Ltd. Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20040220388A1 (en) 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
AU2001283496A1 (en) 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP5133494B2 (ja) 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
ES2466377T3 (es) 2001-08-23 2014-06-10 Rsr Limited Regiones epitópicas de un receptor de tirotropina (TSH), usos de las mismas y anticuerpos para las mismas
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
EP1470159B1 (en) 2001-12-04 2013-08-07 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
GB0208104D0 (en) 2002-04-09 2002-05-22 Univ Dundee Method
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 ｓｃＤｂライブラリーの作成方法
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
ATE348843T1 (de) 2002-11-26 2007-01-15 Brahms Ag Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
EP1641826A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2004289172A1 (en) 2003-06-27 2005-05-26 Diadexus, Inc. Pro 104 antibody compositions and methods of use
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
EP1660534A2 (en) 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
JPWO2005035577A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 ガングリオシドｇｄ３に特異的に結合する抗体組成物
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
CA2550996A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
JP5070045B2 (ja) 2004-05-27 2012-11-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規人工抗原提示細胞およびそれらの用途
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
MX2007014474A (es) * 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
JP2008546699A (ja) 2005-06-15 2008-12-25 シェーリング コーポレイション 抗ｉｇｆ１ｒ抗体処方物
SG163554A1 (en) 2005-07-01 2010-08-30 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602005018477D1 (de) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
JP5512128B2 (ja) 2005-12-08 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
WO2007084342A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US8603466B2 (en) 2006-03-29 2013-12-10 King's College London Agonist antibodies against TSHR
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2007137760A2 (en) 2006-05-25 2007-12-06 Bayer Schering Pharma Aktiengesellschaft Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US8440798B2 (en) 2006-10-04 2013-05-14 Københavns Universitet Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
FR2906808B1 (fr) 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
WO2008101234A2 (en) 2007-02-16 2008-08-21 Sloan-Kettering Institute For Cancer Research Anti ganglioside gd3 antibodies and uses thereof
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
JP5681482B2 (ja) 2007-03-29 2015-03-11 ゲンマブ エー／エス 二重特異性抗体およびその作製方法
EP2514766A3 (en) 2007-03-29 2013-06-05 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8344112B2 (en) 2007-07-31 2013-01-01 Merck Sharp & Dohme Limited IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
EP2178914A2 (en) 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
US9416165B2 (en) 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262504A1 (en) 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US8486393B2 (en) 2008-09-19 2013-07-16 University of Pittsburgh—of the Commonwealth System of Higher Education Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
ES2500643T3 (es) 2009-04-03 2014-09-30 Verastem, Inc. Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5726170B2 (ja) 2009-04-30 2015-05-27 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 抗ｃｅａｃａｍ１抗体およびその使用方法
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
MX340953B (es) 2009-09-03 2016-07-29 Merck Sharp & Dohme Corp * Anticuerpos anti receptor del factor de necrosis tumoral inducido por glucocorticoides.
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
MY165151A (en) 2010-02-24 2018-02-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
AU2011244282A1 (en) 2010-04-20 2012-11-15 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
US9011863B2 (en) 2010-07-09 2015-04-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
EP2593450A1 (en) 2010-07-16 2013-05-22 Piramal Enterprises Limited Substituted imidazoquinoline derivatives as kinase inhibitors
US8945868B2 (en) 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
PL2694549T3 (pl) 2011-04-08 2019-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
ES2953190T3 (es) 2011-05-27 2023-11-08 Glaxo Group Ltd Proteínas de unión a BCMA (CD269/TNFRSF17)
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
WO2013023184A1 (en) 2011-08-11 2013-02-14 Intellikine, Llc Kinase inhibitor polymorphs
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
ITMO20110270A1 (it) 2011-10-25 2013-04-26 Sara Caldrer Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
BR112014010023B1 (pt) 2011-10-27 2023-11-21 Genmab A/S Método in vitro para a produção de um anticorpo biespecífico de comprimento total
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP2785743B1 (en) 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
US9439768B2 (en) 2011-12-08 2016-09-13 Imds Llc Glenoid vault fixation
AU2013216320A1 (en) * 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
CA3084919A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CA2867824A1 (en) 2012-05-01 2013-11-07 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
ES2960803T3 (es) 2012-05-25 2024-03-06 Univ California Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA
WO2013192294A1 (en) 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
EP3698809A1 (en) 2012-07-31 2020-08-26 The Brigham & Women's Hospital, Inc. Modulation of the immune response using agents binding tim-3 and ceacam-1
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
BR112015008118A2 (pt) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc reforço da resposta imune
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20160008399A1 (en) 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
EP3623380A1 (en) * 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3119423B1 (en) 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
TW202508628A (zh) * 2016-07-28 2025-03-01 瑞士商諾華公司 嵌合抗原受體及pd-1抑制劑之組合療法
PH12022551290A1 (en) * 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
IL320155A (en) * 2022-10-18 2025-06-01 Kite Pharma Inc Novel cd19 binders, car-t constructs comprising the same, and methods of using the same
US20240226154A9 (en) * 2022-10-18 2024-07-11 Kite Pharma, Inc. Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same

Also Published As

Publication number Publication date
EP3593812A2 (en) 2020-01-15
EP3119423B1 (en) 2022-12-14
US20170335281A1 (en) 2017-11-23
JP2017513818A (ja) 2017-06-01
JP7526121B2 (ja) 2024-07-31
WO2015142675A3 (en) 2015-11-12
WO2015142675A2 (en) 2015-09-24
JP2024164002A (ja) 2024-11-26
JP6860623B2 (ja) 2021-04-21
EP3593812A3 (en) 2020-05-27
EP3119423A2 (en) 2017-01-25
JP2019206538A (ja) 2019-12-05
CN106163547A (zh) 2016-11-23
JP2021107395A (ja) 2021-07-29
WO2015142675A8 (en) 2016-10-20
US20200283729A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7526121B2 (ja) キメラ抗原受容体を使用する癌の処置
US20230312677A1 (en) Cd28 compositions and methods for chimeric antigen receptor therapy
US20240139244A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US12128069B2 (en) Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20200339651A1 (en) Methods for b cell preconditioning in car therapy
ES2805475T3 (es) Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33
ES2791248T3 (es) Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
US20200048359A1 (en) Shp inhibitor compositions and uses for chimeric antigen receptor therapy
ES2876263T3 (es) Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
US20170274014A1 (en) Combinations of low, immune enhancing, doses of mtor inhibitors and cars
US20180092968A1 (en) Compositions to disrupt protein kinase a anchoring and uses thereof
JP2018527008A (ja) 有効性が増強されたｃａｒ ｔ細胞療法
WO2016126608A1 (en) Car-expressing cells against multiple tumor antigens and uses thereof
US20250163148A1 (en) Anti-car compositions and methods
US20200390811A1 (en) Compositions to disrupt protein kinase a anchoring and uses thereof
WO2024243436A2 (en) Genetically modified cells comprising a heterologous nucleic acid molecule inserted at a cd5 gene locus field